Psychedelic-assisted therapy, minus the hype.
An independent weekly briefing on research, regulation and business in psychedelic medicine worldwide, with the UK & Europe angle nobody else covers, built for clinicians, researchers, clinic operators and investors. Every claim links to a primary source.
Get the Thursday briefing
One email a week. Five-minute read. Free.
Subscribe free →Latest issue
The first half of every issue is free to read here. See all issues →
Europe holds the line, the US gets ready to launch, and Big Pharma buys in
Europe holds the line, the US gets ready to launch, and Big Pharma buys in. Weekly psychedelic therapy news with the UK & Europe angle. Free preview: UK, Europe. Subscribe free for the full issue.
Approval tracker
Where key psychedelic and related programmes stand with regulators. Last reviewed . "—" = not applicable / no sourced status.
| Programme | Indication | Stage | US FDA | UK MHRA | EU / Europe | Updated | Sources |
|---|
About
Evidence first
We summarise regulators, trial registries, peer-reviewed papers and company filings, and we link every claim. Corrections are published openly.
Global, with a UK & Europe lens
We cover the big stories worldwide, from the FDA to the TGA. Most coverage stops at the US, so we also explain what MHRA, NICE, EMA and national programmes mean for the UK and Europe.
Independent
Published by Psyche Vibes Ltd, London. Sponsorships are always clearly labelled and never influence editorial content or the tracker.